Joseph Matus Fuisz, president of Fuisz Pharma, said: “The desirability of an effective anti abuse system is well understood. The US Government has estimated that thirty six million Americans will abuse a medication at some point in their lifetime. Abuse is particularly prevalent in the pain area.
“Notwithstanding this need, the industry has found it challenging to implement abuse resistant dosage forms despite Herculean formulation efforts. This is due primarily to the fundamental tension between the bioavailability of a drug in the body and the prevention of extraction from the dosage form and other types of misuse by a highly motivated and sophisticated population of abusers.
“The Fuisz system for preventing abuse combines, as the best inventions do, novelty with simplicity. We are confident that our anti-abuse system will be welcomed by our pharmaceutical partners as well as by those concerned with drug misuse issues and the public and private health practitioner.”